Neovasc to Report Third Quarter Financial Results on November 10, 2022
27 Octubre 2022 - 8:00AM
via NewMediaWire -- Neovasc Inc. (NASDAQ , TSX :
NVCN) will report financial results for the quarter ended September
30, 2022 on Thursday, November 10, 2022. Neovasc’s President and
Chief Executive Officer Fred Colen, and Chris Clark, Chief
Financial Officer, will host a conference call to review the
company’s results at 4:30 pm ET on November 10, 2022.
Interested parties may access the conference call by dialing
(800) 458-4121 or (856) 344-9290 (International) and reference
Conference ID 7304031. Participants wishing to join the call via
webcast should use the link posted on the investor relations
section of the Neovasc website at neovasc.com/investors/. A
replay of the webcast will be available approximately 30 minutes
after the conclusion of the call using the link on the Neovasc
website.
About Neovasc Inc.Neovasc is a specialty medical device company
that develops, manufactures, and markets products for the rapidly
growing cardiovascular marketplace. Its products include Neovasc
Reducer™, for the treatment of refractory angina, which is under
clinical investigation in the United States and has been
commercially available in Europe since 2015, and Tiara™, a product
under clinical investigation for the transcatheter treatment of
mitral valve disease. The company remains committed to the ongoing
follow-up of patients in Tiara clinical trials and has paused all
other Tiara activities. For more information,
visit: www.neovasc.com.
Forward-Looking Statement DisclaimerCertain statements in this
news release contain forward-looking statements within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995 and
applicable Canadian securities laws that may not be based on
historical fact. When used herein, the words expect, anticipate,
estimate, may, will, should, intend, believe, and similar
expressions, are intended to identify forward-looking statements.
Forward-looking statements may involve, but are not limited to, the
growing cardiovascular marketplace. Forward-looking statements are
based on estimates and assumptions made by the Company in light of
its experience and its perception of historical trends, current
conditions and expected future developments, as well as other
factors that the Company believes are appropriate in the
circumstances. Many factors could cause the Company’s actual
results, performance or achievements to differ materially from
those expressed or implied by the forward-looking statements,
including those described in the Risk Factors section of the
Company’s Annual Report on Form 20-F and in the Management’s
Discussion and Analysis for the three and six months ended June 30,
2022 (copies of which may be obtained
at www.sedar.com or www.sec.gov). These factors
should be considered carefully, and readers should not place undue
reliance on the Company’s forward-looking statements. The Company
has no intention and undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
ContactsInvestors Mike Cavanaugh Westwicke/ICR Phone:
+1.617.877.9641 Email: Mike.Cavanaugh@westwicke.com
Media Sean Leous Westwicke/ICR Phone: +1.646.866.4012
Email: Sean.Leous@icrinc.com
Neovasc (TSX:NVCN)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Neovasc (TSX:NVCN)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024